Optimal dosing of atypical antipsychotics in adults: A review of the current evidence

Harvard Review of Psychiatry

Volumn 10, Issue 5, 2002, Pages 280-291

  Citrome, Leslie ^a,b   Volavka, Jan ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LORAZEPAM; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG LABELING; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GYNECOMASTIA; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MENTAL HEALTH CARE; META ANALYSIS; MULTICENTER STUDY; PARKINSONISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0036735166     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.1080/10673220216279     Document Type: Review

References (91)

1. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.
2. Citrome L, Volavka J. Atypical antipsychotics-evolutionary or incremental advance? Exp Rev Neurother 2002;2:69-88.
3. McGorry PD. The detection and optimal management of early psychosis. In: Lieberman JA, Murray RM, eds. Comprehensive care of schizophrenia: a textbook of clinical management. London, England: Dunitz, 2001:153-66.
4. Siegfried SL, Fleischhacker W, Lieberman JA. Pharmacological treatment of schizophrenia. In: Lieberman JA, Murray RM, eds. Comprehensive care of schizophrenia: a textbook of clinical management. London: Dunitz, 2001:59-94.
5. Krakowski MI, Kunz M, Czobor P, Volavka J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp Community Psychiatry 1993;44:640-4.
6. Volavka J, Cooper TB, Czobor P, Meisner M. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 1995;52:837-45.
7. Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P, et al. High-dose treatment with haloperidol: the effect of dose reduction. J Clin Psychopharmacol 2000;20:252-6.
8. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-8.
9. Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001;62:282-9.
10. Okuma T. Differential sensitivity to the effects of psychotropic drugs: psychotics vs normals; Asian vs Western populations. Folia Psychiatr Neurol Jpn 1981;35:79-87.
11. Citrome L, Levine J, Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull 1996;32:321-6.
12. Levine J, Citrome L, Allingham B. An effectiveness study comparing oral and depot neuroleptic medications [Abstract]. Psychopharmacol Bull 1997;33:476.
13. Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr Q 1998;69:283-300.
14. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000;51:634-8.
15. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996;153:1579-84.
16. Mossman D, Somoza E. ROC curves, test accuracy, and the description of diagnostic tests. J Neuropsychiatry Clin Neurosci 1991;3:330-3.
17. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148:231-5.
18. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993;13:383-90.
19. Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia AG, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 2000;148:83-9.
20. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, et al. Plasma clozapine levels and clinical response for treatment refractory schizophrenic patients. Am J Psychiatry 1995;152:179-82.
21. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(9, suppl B):133-6.
22. Simpson GM, Josiassen RC, Stanilla JK, De Leon J, Nair C, Abraham G, et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry 1999;156:1744-50.
23. Lindenmayer JP, Apergi FS. The relationship between clozapine plasma levels and clinical response. Psychiatr Ann 1996; 6:406-12.
24. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-51.
25. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
26. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses ofrisperidone and haloperidolin the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40.
27. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166:712-26.
28. Potkin SG, Gutierrez R. Safety and efficacy of once-daily risperidone in the treatment of schizophrenia. Presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego, May 1997.
29. Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 2001; 153:238-43.
30. Aravagiri M, Marder SR, Wirshing D, Wirshing WC. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 1998;31:102-9.
31. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999;99:160-70.
32. Love RC, Conley RR, Kelly DL, Bartko JJ. A dose-outcome analysis of risperidone. J Clin Psychiatry 1999;60:771-5.
33. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
34. Kinon BJ, Gilmore JA, Wang L. Exploration of a dose-response relationship in schizophrenia with the novel antipsychotic drug olanzapine. Presented at the 13th Annual US Psychiatric & Mental Health Congress, San Diego, November 2000.
35. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 1997;17:472-7.
36. Chong SA, Remington G. Plasma olanzapine and clinical response [Letter]. J Clin Psychopharmacol 1999;19:192-4.
37. Hiemke C, Gerek S, Weigmann H, Härtter S. Monitoring serum levels of olanzapine [Abstract]. Int J Neuropsychopharmacol 2000;3(suppl 1): S158.
38. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001;21:14-20.
39. Breier A, Meehan K, Birkett MA, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-8.
40. Beasley CM Jr, Beuzen JN, Birkett MA, Kiesler GM, Tollefson GD, Wood AJ. Olanzapine versus clozapine: an international double-blind study of the treatment of resistant schizophrenia. Presented at the 152nd Annual Meeting of the American Psychiatric Association, Washington, DC, May 1999.
41. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001;49:52-63.
42. Dursun SM, Gardner DM, Bird DC, Flinn J. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can J Psychiatry 1999;44:701-4.
43. Sheitman BB, Lindgren JC, Early J, Sved M. High-dose olanzapine for treatment-refractory schizophrenia [Letter]. Am J Psychiatry 1997;154:1626.
44. Mountjoy CQ, Baldacchino AM, Stubbs JH. British experience with high-dose olanzapine for treatment-refractory schizophrenia [Letter]. Am J Psychiatry 1999;156:158-9.
45. Reich J. Use of high-dose olanzapine in refractory psychosis [Letter]. Am J Psychiatry 1999;156:661.
46. Fanous A, Lindenmayer JP. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine [Letter]. J Clin Psychopharmacol 1999;19:275-6.
47. Lindenmayer JP, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M, et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open label, prospective trial. J Clin Psychopharmacol 2001;21:448-53.
48. Baker RW, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF, et al. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 2001.
49. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
50. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-57.
51. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
52. Reinstein MJ, Sonnenberg JG, Chasanov MA, Mohan SC, Patel SA, Gharavi R, et al. Comparative efficacy and tolerability of quetiapine at high and low doses. Presented at the 154th Annual Meeting of the American Psychiatric Association, New Orleans, May 2001.
53. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140:173-84.
54. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505.
55. Reeves KR, Swift RH, Harrigan EP. Intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation. Presented at the 151st Annual Meeting of the American Psychiatric Association, Toronto, June 1998.
56. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine [Letter]. J Clin Psychopharmacol 1994;14:279-81.
57. Eggert AE, Crismon ML, Dorson PG. Lack of effect of fluoxetine on plasma clozapine concentrations [Letter]. J Clin Psychiatry 1994;55:454-5.
58. Kingsbury SJ, Puckett KM. Effects of fluoxetine on serum clozapine levels [Letter]. Am J Psychiatry 1995;152:473-4.
59. DuMortier G, Lochu A, Colen de Melo P, Ghribi O, Roche-Rabreau D, DeGrassat K, et al. Elevated clozapine plasma concentrations after fluvoxamine initiation [Letter]. Am J Psychiatry 1996;153:738-9.
60. Koponen HJ, Leinonen E, Lepola U. Fluvoxamine increases the clozapine levels significantly. Eur Neuropsychopharmacol 1996;6:69-71.
61. Dequardo JR, Roberts M. Elevated clozapine levels after fluvoxamine initiation [Letter]. Am J Psychiatry 1996;153:840-1.
62. Joos AA, König F, Frank UG, Kaschka WP, Mörike KE, Ewald R. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. Pharmacopsychiatry 1997;30:266-70.
63. Armstrong SC, Stephans JR. Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage [Letter]. J Clin Psychiatry 1997;58:499.
64. Borba CP, Henderson DC. Citalopram and clozapine: potential drug interaction [Letter]. J Clin Psychiatry 2000;61:301-2.
65. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
66. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-5.
67. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820-2.
68. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Härtter S, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9.
69. Spina E, Avenoso A, Facciolà G, Fabrazzo M, Monteleone P, Maj M, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:141-5.
70. Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Härtter S, et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999;32:148-53.
71. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000;61:594-9.
72. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995;28:26-8.
73. Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine [Letter]. Am J Psychiatry 1993; 150:169.
74. Seppala NH, Leinonen EV, Lehtonen ML, Kivisto KT. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999;85:244-6.
75. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000; 51:634-8.
76. Costello LE, Suppes T. A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 1995; 15:139-41.
77. Facciolä G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A, Perucca E, et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 1999;21:341-5.
78. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994;36:487-8.
79. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenia. J Clin Psychiatry 1996; 57:395-7.
80. Alfaro CL, Nicolson R, Lenane M, Rapoport JL. Carbamazepine and/or fluvoxamine drug interaction with risperidone in a patient on multiple psychotropic medications [Letter]. Ann Pharmacother 2000;34:122-3.
81. Loonen AJ, Doorschot CH, Oostelbos MC, Sitsen JM. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. Eur Neuropsychopharmacol 1999;10:51-7.
82. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol 1999;39:297-309.
83. Sommers DK, Snyman JR, Van Wyk M, Blom MW, Huang ML, Levron JC. Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients. Int Clin Psychopharmacol 1997;12:141-5.
84. Benazzi F. Gynecomastia with risperidone-fluoxetine combination. Pharmacopsychiatry 1999;32:41.
85. Spina E, Avenoso A, FacciolA G, Salemi M, Scordo MG, Giacobello T, et al. Plasma concentrations ofrisperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000;22:481-5.
86. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 1998;54:639-43.
87. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999;21:87-90.
88. Deshauer D, Albuquerque J, Alda M, Grof P. Seizures caused by possible interaction between olanzapine and clomipramine [Letter]. J Clin Psychopharmacol 2000;20:283-4.
89. Tiihonen J, Hallikainen T, Ryynänen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized, placebo-controlled trial. Presented at the 43rd Annual and 2nd Mediterranean Meeting of the Scandinavian College of Neuro-Psychopharmacology, Juan-les-Pins, France, April 2002.
90. Casey DE, Daniel D, Tracy K, Wozniak P, Sommerville K. Improved antipsychotic effect of divalproex combined with risperidone or olanzapine for schizophrenia. Presented at the 26th Biennial Congress of the World Federation for Mental Health, Vancouver, July 2001.
91. Vartiainen H, Tiihonen J, Putkonen A, Koponen H, Virkkunen M, Hakola P, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995;91:348-51.